All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
An expert panel hosted by
Sequencing immune-based therapies in B-cell malignancies
with Ulric Jäger, Sagar Lonial, and Krina Patel
Saturday, June 15 | 18:00-19:30 CEST
Register nowThis independent education activity is sponsored by Bristol Myers Squibb. All content is developed independently by the faculty. Funders are allowed no direct influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Visual abstract | Auto-HSCT after a rituximab/ibrutinib/Ara-c containing induction in generalized mantle cell lymphoma: TRIANGLE trial
The Lymphoma Hub is pleased to present a visual abstract summarizing results from the phase III TRIANGLE trial (NCT02858258) assessing the safety and efficacy of the addition of ibrutinib, a Bruton’s tyrosine kinase inhibitor, to standard immunochemotherapy with or without autologous hematopoietic stem cell transplantation (auto-HSCT) in younger patients with mantle cell lymphoma. Results from this trial were published by Dreyling et al.1 in The Lancet.
The addition of ibrutinib to standard immunochemotherapy improved outcomes; however, toxicity was increased when ibrutinib was given after auto-HSCT.1 Whether auto-HSCT is beneficial with ibrutinib-based treatment is yet to be determined.1
- Dreyling M, Doorduijn J, Giné E, et al. Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network. 2024. Online ahead of print. DOI: 10.1016/S0140-6736(24)00184-3.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Thank youRelated articles
Newsletter
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox